MONOCLONAL ANTIBODY COVID-19 INFUSION

APPLIES TO: Providers who administer the Monoclonal Antibody COVID-19 Infusion

EFFECTIVE DATE: November 10 and 21, 2020

CONTENTS

- MONOCLONAL ANTIBODY COVID-19 INFUSION
- OUTPATIENT BILLING FOR MONOCLONAL ANTIBODY COVID-19 INFUSION
- APPLICABILITY

MONOCLONAL ANTIBODY COVID-19 INFUSION

The MO HealthNet Division (MHD) is responding to an outbreak of respiratory disease caused by a novel coronavirus. The virus has been named “severe acute respiratory syndrome coronavirus 2” (“SARS-CoV-2”) and the disease it causes has been named “coronavirus disease 2019” (“COVID-19”).

Effective November 10, 2020, providers may bill for administration of the monoclonal antibody COVID-19 infusion of bamlanivimab.

Effective November 21, 2020, providers may bill for the administration of monoclonal antibody COVID-19 therapy infusion of casirivimab and imdevimab, administered together.

Both infusions are for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive COVID-19 test results who are at high risk for progressing to severe COVID-19 and/or hospitalization.

While the federal government is paying for the product, the product cost cannot be billed to MO HealthNet.

Covered procedure codes are listed in the table below.

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Procedure Code Description</th>
<th>Reimbursement Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0239</td>
<td>Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring.</td>
<td>$309.60</td>
</tr>
<tr>
<td>M0243</td>
<td>Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring.</td>
<td>$309.60</td>
</tr>
</tbody>
</table>
OUTPATIENT BILLING FOR MONOCLONAL ANTIBODY COVID-19 INFUSION

Effective November 10, 2020, hospitals may bill for the monoclonal antibody COVID-19 infusion when performed as an outpatient service using revenue code 260 and procedure code M0239. Effective November 21, 2020, hospitals may bill for the monoclonal antibody COVID-19 infusion when performed as an outpatient service using revenue code 260 and procedure code M0243. These procedure codes cover the equipment and personnel needed to provide COVID-19 infusion therapy in the outpatient setting. If these services are the only services provided during the outpatient visit, without any medical professional services, a facility charge must not be billed. Providers will not incur a cost for bamlanivimab and casirivimab/imdevimab, at least initially. Providers should not bill for the product while receiving it for free.

APPLICABILITY
Managed Care enrolled providers should contact their Managed Care Organization for questions regarding Monoclonal Antibody COVID-19 Infusion.

Provider Bulletins are available on the MO HealthNet Division (MHD) (Formerly the Division of Medical Services) Web site at http://dss.mo.gov/mhd/providers/pages/bulletins.htm. Bulletins will remain on the Provider Bulletins page only until incorporated into the provider manuals as appropriate, then moved to the Archived Bulletin page.

MO HealthNet News: Providers and other interested parties are urged to go to the MHD Web site at http://dss.missouri.gov/mhd/global/pages/mednewssubscribe.htm to subscribe to the electronic mailing list to receive automatic notifications of provider bulletins, provider manual updates, and other official MO HealthNet communications via E-mail.

MO HealthNet Managed Care: The information contained in this bulletin applies to coverage for:

- MO HealthNet Fee-for-Service
- MO HealthNet Managed Care

Questions regarding MO HealthNet Managed Care benefits should be directed to the patient’s MO HealthNet Managed Care health plan. Before delivering a service, please check the patient’s eligibility status by swiping the MO HealthNet card or by calling the Provider Communications Interactive Voice Response (IVR) System at 573-751-2896 and using Option One for the red or white card.

Provider Communications Hotline
573-751-2896